162 related articles for article (PubMed ID: 26744260)
21. Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer.
Zhao YQ; Yin YQ; Liu J; Wang GH; Huang J; Zhu LJ; Wang JH
Acta Pharmacol Sin; 2016 Sep; 37(9):1237-50. PubMed ID: 27397540
[TBL] [Abstract][Full Text] [Related]
22. Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition
Yu JK; Yue CH; Pan YR; Chiu YW; Liu JY; Lin KI; Lee CJ
Anticancer Res; 2018 Apr; 38(4):2127-2135. PubMed ID: 29599331
[TBL] [Abstract][Full Text] [Related]
23. Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells.
Mehta R; Katta H; Alimirah F; Patel R; Murillo G; Peng X; Muzzio M; Mehta RG
PLoS One; 2013; 8(6):e65113. PubMed ID: 23762292
[TBL] [Abstract][Full Text] [Related]
24. Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A.
Breen L; Gaule PB; Canonici A; Walsh N; Collins DM; Cremona M; Hennessy BT; Duffy MJ; Crown J; Donovan NO; Eustace AJ
Invest New Drugs; 2020 Oct; 38(5):1365-1372. PubMed ID: 32318883
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
Chen LL; Zhang ZJ; Yi ZB; Li JJ
Br J Cancer; 2017 Jun; 117(1):78-88. PubMed ID: 28571042
[TBL] [Abstract][Full Text] [Related]
27. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
Liu J; Chen X; Ward T; Pegram M; Shen K
Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
[TBL] [Abstract][Full Text] [Related]
28. (-)-Oleocanthal as a c-Met inhibitor for the control of metastatic breast and prostate cancers.
Elnagar AY; Sylvester PW; El Sayed KA
Planta Med; 2011 Jul; 77(10):1013-9. PubMed ID: 21328179
[TBL] [Abstract][Full Text] [Related]
29. The targeted inhibition of Hsp90 by a synthetic small molecule, DPide offers an effective treatment strategy against TNBCs.
Oh YJ; Park SY; Seo YH
Oncol Rep; 2018 Apr; 39(4):1775-1782. PubMed ID: 29436674
[TBL] [Abstract][Full Text] [Related]
30. A novel compound LingH2-10 inhibits the growth of triple negative breast cancer cells in vitro and in vivo as a selective inverse agonist of estrogen-related receptor α.
Ning Y; Chen H; Du Y; Ling H; Zhang L; Chen L; Qi H; Shi X; Li Q
Biomed Pharmacother; 2017 Sep; 93():913-922. PubMed ID: 28715872
[TBL] [Abstract][Full Text] [Related]
31. Validation of a network-based strategy for the optimization of combinatorial target selection in breast cancer therapy: siRNA knockdown of network targets in MDA-MB-231 cells as an in vitro model for inhibition of tumor development.
Tilli TM; Carels N; Tuszynski JA; Pasdar M
Oncotarget; 2016 Sep; 7(39):63189-63203. PubMed ID: 27527857
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
33. Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133
Brugnoli F; Grassilli S; Lanuti P; Marchisio M; Al-Qassab Y; Vezzali F; Capitani S; Bertagnolo V
BMC Cancer; 2017 Sep; 17(1):617. PubMed ID: 28870198
[TBL] [Abstract][Full Text] [Related]
34. Down-regulation of cathepsin S and matrix metalloproteinase-9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis.
Gautam J; Banskota S; Lee H; Lee YJ; Jeon YH; Kim JA; Jeong BS
Exp Mol Med; 2018 Sep; 50(9):1-14. PubMed ID: 30185799
[TBL] [Abstract][Full Text] [Related]
35. E1A-mediated inhibition of HSPA5 suppresses cell migration and invasion in triple-negative breast cancer.
Chen HA; Chang YW; Tseng CF; Chiu CF; Hong CC; Wang W; Wang MY; Hsiao M; Ma JT; Chen CH; Jiang SS; Wu CH; Hung MC; Huang MT; Su JL
Ann Surg Oncol; 2015 Mar; 22(3):889-98. PubMed ID: 25212833
[TBL] [Abstract][Full Text] [Related]
36. Antiproliferative and antimetastatic properties of 3-benzyloxy-16-hydroxymethylene-estradiol analogs against breast cancer cell lines.
Sinka I; Kiss A; Mernyák E; Wölfling J; Schneider G; Ocsovszki I; Kuo CY; Wang HC; Zupkó I
Eur J Pharm Sci; 2018 Oct; 123():362-370. PubMed ID: 30010030
[TBL] [Abstract][Full Text] [Related]
37. Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer.
Zhang S; Chung WC; Miele L; Xu K
Cancer Biol Ther; 2014 May; 15(5):633-42. PubMed ID: 24556651
[TBL] [Abstract][Full Text] [Related]
38. KR-33028, a potent inhibitor of the Na
Amith SR; Wilkinson JM; Fliegel L
Biochem Pharmacol; 2016 Oct; 118():31-39. PubMed ID: 27521504
[TBL] [Abstract][Full Text] [Related]
39. CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers.
Cheriyan VT; Muthu M; Patel K; Sekhar S; Rajeswaran W; Larsen SD; Polin L; Levi E; Singh M; Rishi AK
Oncotarget; 2016 Nov; 7(45):73370-73388. PubMed ID: 27687593
[TBL] [Abstract][Full Text] [Related]
40. The Na⁺/H⁺ exchanger (NHE1) as a novel co-adjuvant target in paclitaxel therapy of triple-negative breast cancer cells.
Amith SR; Wilkinson JM; Baksh S; Fliegel L
Oncotarget; 2015 Jan; 6(2):1262-75. PubMed ID: 25514463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
